Sep. 10 at 10:35 AM
Oppenheimer reitd
$XERS OP-
$18/said--Yesterday's virtual event provided an overview of Xeris Biopharma's clinical, regulatory, and commercial plans for XP-8121, its once-weekly subcutaneous levothyroxine candidate for hypothyroidism.
$ABBV $AMRX SNY PFE MRK
Oppenheimer added —In our view, KOL commentary and the design of the soon-to-begin Phase 3 Cornerstone trial derisk XP-8121's opportunity, aimed at the 3-5M US patients who remain biochemically uncontrolled on oral levothyroxine.
The concurrent Touchstone trial will provide additional real-world evidence of unmet need and clinical differentiation from standard of care.
We see XP-8121 launching in 2030, and management estimated a
$1-3B peak sales opportunity for XP-8121 with up to 10% penetration of the target population over time. Reiterate Outperform.
